73%
of retail accounts lose money when trading CFDs with this provider.
Investments involve risks and are not suitable for all investors. CFDs are complex instruments and come with a high risk of losing money rapidly due to leverage.
73%
of retail investor accounts lose money when trading CFDs with this provider.
You should consider whether you understand how CFDs work, and whether you can afford to take the high risk of losing your money.
73%
of retail accounts lose money when trading CFDs with this provider.
Investments involve risks and are not suitable for all investors. CFDs are complex instruments and come with a high risk of losing money rapidly due to leverage.
73%
of retail investor accounts lose money when trading CFDs with this provider.
You should consider whether you understand how CFDs work, and whether you can afford to take the high risk of losing your money.
English (International)
Vertex Pharmaceuticals Inc
Closed
SectorHealthcare
449.53 -1.1
Overview
Share price change
24h
Min
445.89
Max
454.46
Income | 50M 1.1B |
|---|---|
Sales | 112M 3.1B |
P/E Sector Avg | 32.368 90.831 |
Profit margin | 35.2 |
Employees | 6,100 |
EBITDA | -66M 1.4B |
Recommendations | Strong Buy |
|---|---|
12 Months Forecast | +14.3% upside |
Next Earnings | 9 Feb 2026 |
|---|
Market Cap | 8.9B 118B |
|---|---|
Previous open | 450.63 |
Previous close | 449.53 |
News Sentiment
By Acuity
26%
74%
43 / 361 Healthcare
Technical Score
By Trading Central
Confidence
Very Strong Bearish Evidence
Vertex Pharmaceuticals Inc Chart
Past performance is not a reliable indicator of future results.
Related News
Peer Comparison
Price change
Vertex Pharmaceuticals Inc Forecast
Price Target
By TipRanks
14.3% upside
12 Months Forecast
Average 519.69 USD 14.3%
High 625 USD
Low 414 USD
Based on 22 Wall Street analysts offering 12 month price targets forVertex Pharmaceuticals Inc - Dist in the last 3 months.
Sentiment
By Acuity
43 / 361 Healthcare
News Sentiment
Bullish Evidence
Volatility
Below average
News Volume (RCV)
Above average
Financials
Selling and administration expenses
Operating expenses
Pre-tax profit
Sales
Cost of sales
Gross profit on sales
Interest expense on debt
EBITDA
Operating profit
$
About Vertex Pharmaceuticals Inc
Vertex Pharmaceuticals Incorporated, a biotechnology company, engages in developing and commercializing therapies for treating cystic fibrosis (CF). It markets TRIKAFTA/KAFTRIO for people with CF with at least one F508del mutation for 2 years of age or older; SYMDEKO/SYMKEVI for people with CF for 6 years of age or older; ORKAMBI for CF patients 1 year or older; and KALYDECO for the treatment of patients with 1 year or older who have CF with ivacaftor. The company's pipeline includes VX-522, a CFTR mRNA therapeutic designed to treat the underlying cause of CF, which is in Phase 1 clinical trial; VX-548, a non-opioid medicine for the treatment of acute and neuropathic pain which is in Phase 3 clinical trial; Exa-cel, for the treatment of sickle cell disease and transfusion-dependent beta thalassemia which is in Phase 2/3 clinical trial. In addition, it provides inaxaplin for the treatment of APOL1-mediated focal segmental glomerulosclerosis and co-morbidities, such as hypertension which is in single Phase 2/3; VX- 880 and VX-264, treatment for Type 1 Diabetes which is in Phase 1/2 clinical trial; VX-970, which is in Phase 2 clinical trial for the treatment of cancer; and VX-803 and VX-984 for treatment of cancer in Phase 1 clinical trial. Further, it sells the products to specialty pharmacy and specialty distributors in the United States, as well as retail pharmacies, hospitals, and clinics. Additionally, the company has collaborations with CRISPR Therapeutics AG.; Moderna, Inc.; Entrada Therapeutics, Inc.; Arbor Biotechnologies, Inc.; Mammoth Biosciences, Inc.; and Verve Therapeutics., as well as collaborations with Tevard Biosciences to develop novel tRNA-based therapies for duchenne muscular dystrophy. Vertex Pharmaceuticals Incorporated was founded in 1989 and is headquartered in Boston, Massachusetts.
Live chat